Related Experiment Video

Updated: May 24, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

GLP-1 RAs May Prevent Metastatic Progression

    Cancer Discovery
    |May 23, 2026
    PubMed

    Insights

    Glucagon-like-peptide (GLP)-1 receptor agonists may prevent early-stage obesity-related cancers from progressing. Further research is needed before widespread prescription for newly diagnosed patients.

    Area of Science:

    • Oncology
    • Endocrinology
    • Pharmacology

    Background:

    • Obesity-related cancers pose a significant health burden.
    • GLP-1 receptor agonists are established treatments for type 2 diabetes and obesity.
    • The potential role of GLP-1 receptor agonists in cancer progression is an emerging area of research.

    Purpose of the Study:

    • To investigate the potential of GLP-1 receptor agonists in preventing the advancement of early-stage obesity-related cancers.
    • To explore the association between GLP-1 receptor agonist initiation and cancer stage progression.

    Main Methods:

    • Retrospective analysis of patient data.
    • Inclusion of patients diagnosed with stage I, II, or III lung, breast, colorectal, or liver cancers.
    • Comparison of cancer progression rates in patients who initiated GLP-1 receptor agonists versus those who did not.

    Main Results:

    • Preliminary findings suggest that GLP-1 receptor agonist use following diagnosis may be associated with a reduced risk of cancer advancement to stage IV.
    • The observed effect was noted in specific obesity-related cancers including lung, breast, colorectal, and liver cancers.

    Conclusions:

    • GLP-1 receptor agonists show potential as a preventative therapy against the progression of certain early-stage obesity-related cancers.
    • Additional clinical trials are necessary to confirm the efficacy and safety of GLP-1 receptor agonists for this indication before clinical adoption.

    More Related Videos

    An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

    An Orthotopic Murine Model of Human Prostate Cancer Metastasis

    Published on: September 18, 2013

    Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer07:13

    Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

    Published on: March 26, 2014

    Related Concept Videos

    The Ras Gene02:38

    The Ras Gene

    The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
    Ras is a superfamily...
    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...